A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy
Phase of Trial: Phase II/III
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Talditercept alfa (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Chugai Pharmaceutical; Roche
- 10 Jul 2018 Planned End Date changed from 30 Jul 2020 to 17 Dec 2021.
- 10 Jul 2018 Planned primary completion date changed from 30 Jul 2020 to 30 Dec 2020.
- 03 May 2018 Status changed from active, no longer recruiting to recruiting.